Halozyme Therapeutics reported $15.92M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.95M 0.39M
Alnylam Pharmaceuticals ALNY:US $ 35.63M 2.04M
Amarin AMRN:US $ 22.24M 8.4M
Amgen AMGN:US $ 1561M 157M
Esperion Therapeutics ESPR:US $ 7.12M 2.05M
Halozyme Therapeutics HALO:US $ 15.92M 5.66M
Intrexon XON:US $ 15.45M 0.42M
IONIS PHARMACEUT IONS:US $ 4.17M 1.94M
JAZZ PHA JAZZ:US $ 115.28M 20.87M
Nektar Therapeutics NKTR:US $ 6.16M 0.85M
Peregrine Pharmaceuticals PPHM:US $ 16.92M 2.44M